Emerging class of therapeutics represents a coming wave for developers and manufacturers

January 22, 2014

After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.

Ann M. Thayer, senior correspondent at C&EN, explains that ADCs are essentially molecular missiles. They are made up of a toxic payload (a drug) attached to an antibody that specifically seeks out sick cells, such as tumor cells. They don't release their lethal cargo until they reach their target. The advantages of this approach are clear: It spares healthy cells and lowers drug side effects. It can also extend the life of a under an expiring patent or salvage an antibody that was ineffective by itself. ADCs hold a lot of promise. Of the two approved ADCs, one is soon expected to be a blockbuster. About 30 more are in clinical trials with another 100 or more ADCs in the preclinical pipeline. Projections show that by 2018, sales of ADCs could top $5 billion.

On the manufacturing side, because these drugs are so complex, suppliers are still figuring out how to streamline production. At the moment, ADCs are a niche area of manufacturing with only a few contract manufacturing organizations able to put all the pieces together from start to finish. But many are responding and investing millions to expand capacity for this promising new class.

Explore further: Nanomedicines promise fewer side effects in treating cancer

More information: "Building Antibody-Drug Conjugates" cen.acs.org/articles/92/i3/Building-Antibody-Drug-Conjugates.html

Related Stories

Nanomedicines promise fewer side effects in treating cancer

June 6, 2012

A new generation of cancer treatments based on nanotechnology is making its way out of the laboratory and into the clinic with the promise of targeting cancer cells while steering clear of healthy tissue, according to the ...

Shifting the Internet into high gear

March 27, 2013

(Phys.org) —A new-generation analog-to-digital converter (ADC) developed by a joint IBM-EPFL team has the potential to greatly increase the speed and volume of data that can be transferred over the Internet.

Recommended for you

New method developed for producing some metals

August 25, 2016

The MIT researchers were trying to develop a new battery, but it didn't work out that way. Instead, thanks to an unexpected finding in their lab tests, what they discovered was a whole new way of producing the metal antimony—and ...

Electron microscopy reveals how vitamin A enters the cell

August 25, 2016

Using a new, lightning-fast camera paired with an electron microscope, Columbia University Medical Center (CUMC) scientists have captured images of one of the smallest proteins in our cells to be "seen" with a microscope.

Hitching a ride: Misfiring drugs hit the wrong targets

August 25, 2016

It probably isn't surprising to read that pharmaceutical drugs don't always do what they're supposed to. Adverse side effects are a well-known phenomenon and something many of us will have experienced when taking medicines.

Using light to control genome editing

August 25, 2016

The genome-editing system known as CRISPR allows scientists to delete or replace any target gene in a living cell. MIT researchers have now added an extra layer of control over when and where this gene editing occurs, by ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.